NYR
Director Trades
| Date | Director | Value |
|---|---|---|
| J. Moore | $425,625 | |
| M. Frampton | $113,125 |
Company News
Nyrada Confirms Xolatryp Offers Mitochondrial Stabilisation after Traumatic Brain Injury
Nyrada (ASX: NYR) has confirmed its small molecule therapy Xolatryp can reduce mitochondrial calcium ion loading in the brain following traumatic injury. A collaborative study with the University of New South Wales and the Walter Reed Army Institute of Research sought to evaluate the efficacy of Xolatryp in a penetrating traumatic brain injury (TBI) rodent […]
Weekly wrap: rumours of wars send the ASX 200 tumbling
It is the Bible that talks about not being alarmed by “wars and rumours of wars” but Australian share market investors weren’t quite so sanguine, pushing down the ASX 200 sharply. By the close of trade on Friday 55.2 points or 0.7% had been erased from the ASX 200 as the reality of a worsening […]
Nyrada’s NYR-BI03 shows significant cardioprotective efficacy in preclinical study
A preclinical rat study using Nyrada’s (ASX: NYR) lead drug candidate NYR-BI03 has demonstrated up to 86% efficacy in limiting cardiovascular damage associated with coronary heart disease following acute myocardial ischaemic-reperfusion injury. The findings are believed to position NYR-BI03 as a novel cardioprotective treatment following myocardial infarction, which is a leading cause of morbidity and […]
Market wrap: record high ASX 200 follows on from optimism on rates
Australian shares hit a record high on Friday after rising six days out of seven as global optimism on falling interest rates remained high. The ASX 200 finished Friday up 0.6% at a record 7745.6 points for a weekly gain of 1.3% – the biggest weekly rise for a month – as pundits cautiously predicted […]
Nyrada NYR-BI03 trial success heralds breakthrough in stroke and brain injury treatment
Drug discovery and development company Nyrada (ASX: NYR) has announced positive results from a pre-clinical study evaluating lead candidate NYR-BI03 in the prevention of secondary brain injury. The drug is part of the company’s program seeking to develop therapies to reduce the long-term disabilities associated with stroke or traumatic brain injury (TBI) by limiting progressive cell […]
Nyrada reveals encouraging cholesterol-lowering drug study results
Australian biotech Nyrada Inc (ASX: NYR) has reported encouraging pre-clinical results from its drug development program to treat patients with high cholesterol. The company today told the market the results indicate the potential to develop a single pill treatment for hypercholesterolemia to replace expensive ongoing injections. Nyrada has been conducting a study using healthy donor […]
Nyrada announces progress in brain injury study
Nyrada (ASX: NYR) has achieved a milestone in one of its drug development programs for the treatment of brain injury, revealing its lead candidate compounds can cross the blood-brain barrier in the intact, uninjured animal brain. The biotech junior’s brain injury program aims to develop a neuroprotectant drug to reduce secondary brain damage following head […]
Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m
Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8.5 million under the ticker ‘NYR’. Nyrada was established by ASX-listed company Noxopharm to advance its non-oncology drug assets. Following the listing, Noxopharm now owns 30.51% […]
Nyrada advances brain injury and cholesterol lowering studies, remains unaffected by COVID-19
Nyrada (ASX: NYR) revealed this morning it was continuing to make “strong progress” in its two lead drug programs to treat brain injury and lower cholesterol. The brain injury program is using a neuroprotectant drug to reduce secondary brain damage following head trauma (motor vehicle accidents, sporting injuries, falls) or stroke. Following an initial trauma, […]
Nyrada CEO James Bonnar discusses the company’s commercialisation plans – Podcast
Junior biotech company Nyrada (ASX: NYR) was the first IPO off the mark for 2020, with the company’s stock floating on the ASX in mid-January after raising the intended maximum of A$8.5 million. The Noxopharm spinout is pursuing novel treatments for cardiovascular and neurological diseases. Speaking with Small Caps, Nyrada chief executive officer James Bonnar […]
